This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mefloquine (neuropsychiatric adverse reactions)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the prevalence of neuropsychiatric adverse reactions is between 1 in 10,000 and 1 in 20,000 users of prophylactic mefloquine
  • risk is generally higher in females than males
  • mefloquine is contraindicated in patients at risk of seizures, epilepsy or psychiatric disease
  • mefloquine chemoprophylaxis should be used with caution in airline pilots
  • neuropsychiatric adverse reactions account for about 1/4 of side-effects associated with mefloquine
    • 41% of neuropsychiatric adverse reactions occur within one week of starting to take mefloquine
    • 69% of neuropsychiatric adverse reactions occur within two weeks of starting to take mefloquine
    • 78% of neuropsychiatric adverse reactions occur within three weeks of starting mefloquine chemoprophylaxis
  • the commonest symptoms are:
    • vertigo, dizziness and headaches
    • mood changes are a frequently reported symptom
  • serious adverse reactions include psychotic episodes, seizures, ataxia, hallucinations and depression

Roche have stated that (3):

  • Lariam (mefloquine) may induce potentially serious neuropsychiatric disorders

  • the most common neuropsychiatric reactions to mefloquine include abnormal dreams, insomnia, anxiety, and depression. Additionally hallucinations, psychosis, suicide, suicidal thoughts and self-endangering behaviour have been reported

  • do not use mefloquine for malaria chemoprophylaxis in patients with any active or a history of psychiatric disturbances

  • due to the long half-life of mefloquine, adverse reactions may occur and persist up to several months after discontinuation of the drug

  • healthcare professionals should react promptly to signs of neuropsychiatric reactions with mefloquine chemoprophylaxis. Mefloquine should be discontinued immediately and replaced by alternative malaria prophylaxis medication

  • advise patient that if they experience a neuropsychiatric reaction such as suicidal thoughts; self-endangering behaviour; severe anxiety; feelings of restlessness, confusion, or mistrust towards others; visual/auditory hallucinations; depression; or changes to their mental state during mefloquine chemoprophylaxis, they should stop taking mefloquine immediately and seek urgent medical advice

Reference:

  • Prescribers' Journal (1999), 39 (3), 161-5.
  • Health protection agency 2007. Guidelines for malaria prevention in travelers from the United Kingdom
  • Roche (October 2013). Direct Helathcare Professional Communication on Larium (mefloquine) for malaria chemoprophylaxisis and the risk of neuropsychiatric adverse reactions

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.